证券日报网讯12月12日晚间，北陆药业（300016）发布公告称，近日公司收到国家药品监督管理局核准 签发的吡格列酮二甲双胍片(15mg/500mg)的《药品注册证书》，按照化学药品3类获批，视同通过仿制 药质量和疗效一致性评价。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug Pioglitazone Metformin Tablets (15mg/500mg), enhancing its diabetes medication product line and market competitiveness [1] Group 1: Product Approval - The Pioglitazone Metformin Tablets (15mg/500mg) have been approved as a Class 3 chemical drug, indicating it has passed the consistency evaluation for generic drug quality and efficacy [1] - This approval allows the company to expand its diabetes treatment offerings, which is expected to strengthen its position in the market [1] Group 2: Market Strategy - The company plans to actively prepare for the launch of the new product and aims to bring it to market as soon as possible [1] - There may be uncertainties affecting the production and sales of the new product, which the company will need to navigate [1]